Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Homeodomain-interacting protein kinase 2
(
HIPK2
) is an emerging regulator of cell growth and apoptosis in various cell types, tissues and organisms. Previous work indicates that
HIPK2
is a potential
tumour suppressor
and DNA damage-responsive kinase, which phosphorylation-dependently activates the apoptotic programme by engaging diverse downstream targets, including
tumour suppressor
p53 and the anti-apoptotic transcriptional corepressor C-terminal binding protein. The regulation of
HIPK2
, however, remained largely obscure. Recent studies show that
HIPK2
activity is mainly controlled at the post-transcriptional level through targeted proteolysis. Caspase-dependent processing triggers
HIPK2
hyperactivation, whereas the ubiquitin-proteasome system (UPS) keeps
HIPK2
in check by targeting it for degradation. Both
HIPK2
hyperactivation and
HIPK2
degradation are under the control of transcription factor p53. Negative regulation of
HIPK2
by the UPS is abolished in response to DNA damage, which facilitates
HIPK2
stabilization and activation. Here we discuss these findings in the context of DNA damage signalling and tumour suppression.
...
PMID:How cells switch HIPK2 on and off. 1897 74
The
tumour suppressor
p53 is activated to induce cell-cycle arrest or apoptosis in the DNA damage response (DDR). p53 phosphorylation at Ser46 by HIPK2 (
homeodomain-interacting protein kinase 2
) is a critical event in apoptosis induction. Interestingly, HIPK2 is degraded by Mdm2 (a negative regulator of p53), whereas Mdm2 is downregulated by HIPK2 through several mechanisms. Here, we develop a four-module network model for the p53 pathway to clarify the role of interplay between Mdm2 and HIPK2 in the DDR evoked by ultraviolet radiation. By numerical simulations, we reveal that Mdm2-dependent HIPK2 degradation promotes cell survival after mild DNA damage and that inhibition of HIPK2 degradation is sufficient to trigger apoptosis. In response to severe damage, p53 phosphorylation at Ser46 is promoted by the accumulation of HIPK2 due to downregulation of nuclear Mdm2 in the later phase of the response. Meanwhile, the concentration of p53 switches from moderate to high levels, contributing to apoptosis induction. We show that the presence of three mechanisms for Mdm2 downregulation, i.e. repression of mdm2 expression, inhibition of its nuclear entry and HIPK2-induced degradation, guarantees the apoptosis of irreparably damaged cells. Our results agree well with multiple experimental observations, and testable predictions are also made. This work advances our understanding of the regulation of p53 activity in the DDR and suggests that HIPK2 should be a significant target for cancer therapy.
...
PMID:Interplay between Mdm2 and HIPK2 in the DNA damage response. 2482 83